Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy

Gene Therapy
Elena MitrofanovaCharles Link

Abstract

Efficient gene delivery is a critical obstacle for gene therapy that must be overcome. Until current limits of gene delivery technology are solved, identification of systems with bystander effects is highly desirable. As an anticancer agent, radioactive iodine (131)I has minimal toxicity. The physical characteristics of (131)I decay allow radiation penetration within a local area causing bystander killing of adjacent cells. Accumulation of (131)I mediated by the sodium iodide symporter (NIS) provides a highly effective treatment for well-differentiated thyroid carcinoma. Other types of cancer could also be treated by NIS-mediated concentration of lethal (131)I radiation in tumor cells. Our group and others previously reported that a significant antitumor effect in mice was achieved after adenoviral delivery of rat or human NIS gene following administration of 3 mCi of (131)I. We have also demonstrated 5-6-fold greater uptake of (125)I by rat NIS over human NIS in human cancer cells. Recently, we reported the capability of the rat NIS and (131)I to effectively induce growth arrest of relatively large tumors (approximately 800 mm(3)) in an animal model. In the present work tumor growth inhibition was achieved using adenoviral del...Continue Reading

References

Jan 1, 1985·Auris, Nasus, Larynx·Y UmetaniT Kumoi
Sep 13, 1996·Biochemical and Biophysical Research Communications·P A SmanikS M Jhiang
May 27, 1997·Proceedings of the National Academy of Sciences of the United States of America·O LevyN Carrasco
Dec 5, 1998·Clinical Immunology and Immunopathology·T KotaniS Ohtaki
Dec 16, 1998·The Journal of Clinical Endocrinology and Metabolism·L WartofskyI D Hay
May 12, 2000·JAMA : the Journal of the American Medical Association·P W GrigsbyJ O Eichling
Nov 13, 2001·Gene Therapy·C SpitzwegJ C Morris
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John T WeiMartin G Sanda
Feb 18, 2003·Endocrine Reviews·Orsolya DohánNancy Carrasco
Mar 22, 2003·Blood·David DingliStephen J Russell
Mar 10, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Thomas Groot-WassinkGeorges Vassaux
Oct 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elena MitrofanovaCharles Link

❮ Previous
Next ❯

Citations

Jun 28, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·W ChaiS Hu
Mar 25, 2014·Dose-response : a Publication of International Hormesis Society·M D GowC E Mothersill
Apr 28, 2020·Cancer Cell International·Mohsen KeshavarzAmir Ghaemi
Oct 11, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Susanna C ConcilioStephen J Russell
May 14, 2021·Molecular Therapy Oncolytics·Susanna C ConcilioKah-Whye Peng

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.